×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ABBV – abbvie inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ABBV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/29
09:00 am
abbv
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
Low
Report
Allergan Aesthetics* to showcase 360° approach to clinical practice, aesthetic products, and patients with expert-led symposia at AMWC 2023
3/29
01:25 am
abbv
CEOs Have a Poor View of Britain, Says Pharma Lobby Boss [BNN Bloomberg (Canada)]
Low
Report
CEOs Have a Poor View of Britain, Says Pharma Lobby Boss [BNN Bloomberg (Canada)]
3/27
11:12 am
abbv
Imbruvica Market Share and Forecast till 2028 [MarketWatch]
Low
Report
Imbruvica Market Share and Forecast till 2028 [MarketWatch]
3/23
06:30 pm
abbv
Contraceptive Drugs Market Report 2023: Rising Consumer Consciousness around Family Planning Fuels Growth [Daily Finance]
Low
Report
Contraceptive Drugs Market Report 2023: Rising Consumer Consciousness around Family Planning Fuels Growth [Daily Finance]
3/23
09:00 am
abbv
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
Low
Report
AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus
3/23
08:30 am
abbv
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
Low
Report
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis
3/22
08:45 am
abbv
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
Low
Report
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug Application
3/20
04:48 pm
abbv
AbbVie Inc. stock outperforms competitors on strong trading day [MarketWatch]
Low
Report
AbbVie Inc. stock outperforms competitors on strong trading day [MarketWatch]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/28
04:40 pm
abbv
Form 8-K AbbVie Inc. For: Mar 28
Low
Report
Form 8-K AbbVie Inc. For: Mar 28
3/28
11:58 am
abbv
Form PX14A6G AbbVie Inc. Filed by: Chevedden John
Low
Report
Form PX14A6G AbbVie Inc. Filed by: Chevedden John
3/28
06:02 am
abbv
Form PX14A6G AbbVie Inc. Filed by: Friends Fiduciary Corp
Low
Report
Form PX14A6G AbbVie Inc. Filed by: Friends Fiduciary Corp
3/21
05:23 pm
abbv
Form ARS AbbVie Inc. For: Dec 31
Low
Report
Form ARS AbbVie Inc. For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
AbbVie: $63 Billion Allergan Acquisition Just What The Doctor Ordered [Seeking Alpha]
3.7%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/26 Form PX14A6G AbbVie Inc. Filed by: United Church Funds, Inc. 9.7%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
3/23 Abbvie: Buy The Coronavirus Dip For These 3 Reasons [Seeking Alpha] 4.5%
2/7 Q4/2019 12/31/2019 EPS 2.210 ZacksConsensus 2.200 ActVsEst 0.010 - Beat 4.6%
3/19 Israel OKs use of generic AbbVie drug to treat coronavirus despite patent [Reuters (UK)] 4.7%
3/3 Form 4 AbbVie Inc. For: Feb 28 Filed by: Schumacher Laura J 4.8%
3/26 Form PX14A6G AbbVie Inc. Filed by: United Church Funds, Inc. 9.7%
6/26 AbbVie Inc (NYSE: ABBV) had its "hold" rating re-affirmed by analysts at Citigroup Inc. 3.2%
8/16 Form 4 AbbVie Inc. For: Aug 14 Filed by: Gosebruch Henry O 3.3%
11/8 AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia 3.6%
6/25 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript) [Seeking Alpha] 3.6%
TOP News Decliners
2/24
Form 4 AbbVie Inc. For: Feb 20 Filed by: Durkin Brian L
-3.9%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
6/25 AbbVie nears deal to buy Allergan for more than $60 bln - WSJ [Reuters] -11.8%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
3/12 AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia -4.1%
3/20 Form 4 AbbVie Inc. For: Mar 18 Filed by: Durkin Brian L -6.5%
6/25 AbbVie nears deal to buy Allergan for more than $60 bln - WSJ [Reuters] -11.8%
2/12 Results from Chinese drug trials for coronavirus due in weeks: expert [Reuters (UK)] -2.6%
4/7 Form PX14A6G AbbVie Inc. Filed by: ZEVIN ASSET MANAGEMENT LLC -2.6%
3/17 AbbVie and Allergan Sign Consent Decree Agreement with Federal Trade Commission Staff on Pending Transaction -2.7%
2/27 AbbVie Inc (NYSE: ABBV) is now covered by analysts at Barclays PLC. They set an "equal weight" rating on the stock. -2.9%
3/10 Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha] -3.0%
10/1 Lanny's October Dividend Stock Watch List [Seeking Alpha] -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: